Pharmaceutical

Moxifloxacin by Laboratorios Sophia for Bacterial Conjunctivitis: Likelihood of Approval

Moxifloxacin is under clinical development by Laboratorios Sophia and currently in Phase I for Bacterial Conjunctivitis.

May 19, 2024 - 04:00
Moxifloxacin by Laboratorios Sophia for Bacterial Conjunctivitis: Likelihood of Approval
Moxifloxacin is under clinical development by Laboratorios Sophia and currently in Phase I for Bacterial Conjunctivitis.
Read the original article

Tags:

Previous Article

CinDome Pharma secures $40m to advance gastroparesis treatment

Next Article

TNT-119 by Eliem Therapeutics for Membranous Glomerulonephritis: Likelihood of A...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: In the case of a devastating disease, the FDA weighs an experimental drug’s muddled data and a desperate need

STAT+: In the case of a devastating disease, the FDA we...

Aug 15, 2023

STAT+: Breast cancer drug from AstraZeneca, Daiichi hits goal in late-stage trial

STAT+: Breast cancer drug from AstraZeneca, Daiichi hit...

Sep 22, 2023

Futura Medical and Haleon partner to commercialise Eroxon gel in US

Futura Medical and Haleon partner to commercialise Erox...

Jul 17, 2023